Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombopoietin for platelet transfusion refractoriness in thalassemia major undergoing HSCT
ChiCTR-IIR-17011369Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jun 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin in beta thalassemia major and platelet transfusion refractoriness (PTR) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: platelet count. Started Jun 2017; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
beta thalassemia majorplatelet transfusion refractoriness (PTR)
Beyond the preview
Go deeper on ChiCTR-IIR-17011369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17011369.